Clinical Trials
18 trialsNCT07217496 2026-03-17
N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer
University of California, San Francisco
Phase 1 Withdrawn
NCT06190249 2025-06-05
Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma
Case Comprehensive Cancer Center
Phase 1 Withdrawn
NCT05894447 2024-04-12
Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in Patients With Urothelial Cancers
Weill Medical College of Cornell University
Phase 1 Withdrawn
NCT05171062 2023-07-20
Dose Escalation Trial of Bexmarilimab (FP-1305) Plus Pembrolizumab in Non-Small Cell Lung Cancer
The University of Texas Health Science Center at San Antonio
Phase 1 Withdrawn
NCT05431582 2023-06-15
Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT05220748 2023-04-19
RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced CuSCC and HNSCC
Rakuten Medical, Inc.
Phase 1 Withdrawn
NCT05093387 2022-11-15
SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast Cancer
Northwestern University
Phase 1 Withdrawn
NCT04605614 2022-06-09
64Cu-DOTA-pembrolizumab PET for the Study of PD1 Expression
City of Hope Medical Center
Phase 1 Withdrawn
NCT04611139 2022-03-02
Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers
HonorHealth Research Institute
Phase 1 Withdrawn
NCT03245177 2021-07-28
PARIS
The Christie NHS Foundation Trust
Phase 1 Withdrawn
NCT03773744 2021-04-06
Pelican
Turnstone Biologics, Corp.
Phase 1 Withdrawn
NCT03189186 2021-04-05
Phase-I Trial of Pembrolizumab and Percutaneous Cryoablation Combination Followed by Nephron-Sparing Surgery or Cytoreductive Nephrectomy in Locally Advanced and Metastatic Renal Cell Carcinomas
University of California, Irvine
Phase 1 Withdrawn
NCT03605589 2021-04-01
Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma
Children's Hospital Medical Center, Cincinnati
Phase 1 Withdrawn
NCT04201145 2020-11-17
Pembrolizumab + Defactinib In Pleural Mesothelioma
Dana-Farber Cancer Institute
Phase 1 Withdrawn
NCT03617224 2020-04-22
Pembrolizumab and Total Skin Electron Beam Radiotherapy in Mycosis Fungoides and Sézary Syndrome
University of Texas Southwestern Medical Center
Phase 1 Withdrawn
NCT04279938 2020-02-21
A Phase Ib Combination Study of Rituximab, TinostamustinEAnd CHeckpoint Inhibition With Pembrolizumab in Relapsed/Refractory DLBCL
Royal Marsden NHS Foundation Trust
Phase 1 Withdrawn
NCT02880345 2019-04-23
RADVAXâ„¢: A Trial of Combined Pembrolizumab and Hypofractionated Radiation in Patients With Advanced Urothelial Cancer Who Have Progressed on Anti-PD-1/PD-L1 Monotherapy
Abramson Cancer Center at Penn Medicine
Phase 1 Withdrawn
NCT03166254 2019-04-12
Personalized Therapeutic Anti-tumor Vaccine With Pembrolizumab and Standard of Care Chemotherapy in Squamous Non-Small Cell Lung Cancer and Extensive Stage Small Cell Lung Cancer
Washington University School of Medicine
Phase 1 Withdrawn